Brussels, 04/07/2013 (Agence Europe) - On Thursday 4 July, the General Court of the European Union annulled the European Commission's decision refusing to grant a marketing authorisation (MA) for Orphacol, a medicine developed by the Laboratoires CTRS for the treatment of severe, albeit rare, liver disorders. The Court ruled that the orphan medicine could be marketed on the basis of well-established medicinal use dating back more than ten years.
In its decision of 25 May 2012, the...